Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease

Klenske E, Osaba L, Nagore D, Rath T, Neurath M, Atreya R (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Journal of Crohns & Colitis Elsevier

Book Volume: 13

Pages Range: 267-269

Journal Issue: 2

DOI: 10.1093/ecco-jcc/jjy153

Abstract

Ustekinumab [UST] therapy during pregnancy has not yet been extensively evaluated in patients with Crohn's disease. Here, we present the case of a 24-year-old woman with therapy-refractory Crohn's disease, who was treated with UST until Week 30 of pregnancy and successfully delivered a healthy baby boy, who had normal development in the follow-up period of one year. The cord blood UST level was markedly higher than the measured maternal serum drug level. The trough level in the breast milk after re-initiating postpartum UST therapy was initially in the same range as the corresponding serum trough level, and then decreased during maintenance therapy. This is one of the first reports describing the drug levels in the breast milk after re-initiating UST treatment in a Crohn's disease patient.

Authors with CRIS profile

Markus Neurath Lehrstuhl für Innere Medizin I Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)

Involved external institutions

Progenika Biopharma ES Spain (ES)

How to cite

APA:

Klenske, E., Osaba, L., Nagore, D., Rath, T., Neurath, M., & Atreya, R. (2019). Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease. Journal of Crohns & Colitis, 13(2), 267-269. https://dx.doi.org/10.1093/ecco-jcc/jjy153

MLA:

Klenske, Entcho, et al. "Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease." Journal of Crohns & Colitis 13.2 (2019): 267-269.

BibTeX: Download